Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans

Sleep Clinical Trial

Official title:

Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03576664
• Other study ID #: sleepgf
• Secondary ID: H-16045933
• Status: Completed
• Phase: Early Phase 1
• Start date: August 28, 2018
• Est. completion date: October 1, 2019

Study information

• Verified date: November 2022
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The project is aimed at identifying how the adrenergic antagonist 'carvedilol' modulates the effects of sleep deprivation in healthy volunteers. The study is a double-blind, randomized, placebo-controlled, cross-over study. Investigators will include 20 healthy volunteers who will undergo three functional magnetic resonance (fMRI) imaging sessions, one at baseline, and two after sleep deprivation (one night without sleep). The two sleep-deprivation scans are performed in a randomized order where subjects receive placebo or carvedilol, in a within-subject, cross-over study design.

The following domains will be described: 1) fMRI imaging of cerebrospinal fluid (CSF) pulsations (glymphatic flow) in the human brain, performed by a combination of fMRI protocols that includes structural (T1, T2, diffusion weighted) and functional (multiband/fast imaging, spectroscopy) imaging. 2) fMRI imaging during wakefulness and sleep are determined by simultaneous electroencephalographic (EEG) recordings. 3) The effects of sleep deprivation on the fMRI derived glymphatic flow signal. 4) The effects of the adrenergic antagonist carvedilol on fMRI measurements and sleep intensity. 5) Quantification of cognitive performance before and after a nap in the MRI. Cognitive testing includes: assessments of visual attention, reaction time, paired-associative memory, working memory, emotional recognition and subjective ratings of sleepiness and mood.

Description:

Aims and background:

Sleep is a universal biological process. Lack of, or insufficient sleep, has been associated with a range of diseases including obesity, cardiovascular disease, reduced cognition, impaired learning, and increased risk of motor vehicle accidents. Sleep is also associated with neuromolecular alterations in the brain, including reduced firing of arousal maintaining epinephrine and norepinephrine neurons.

A novel molecular function of sleep known as the glymphatic system has recently been described in rodents. This system is specifically activated during non-rapid eye movement (NREM) sleep, and glymphatic flow appear strongly enhanced during sleep when compared to wakefulness. Moreover, it has been shown that adrenergic antagonists enhance glymphatic clearance and flow in rodents. This study aims at applying newly developed functional magnetic resonance imaging (fMRI) protocols to investigate the extent of the glymphatic system non-invasively in humans.

In order for us to quantify the change in glymphatic clearance between sleep and wakefulness, it is necessary to measure the glymphatic process in both vigilance states, requiring that volunteers nap in the MRI scanner. Moreover, to clarify causal relationships, this study will challenge the glymphatic system via adrenergic inhibition. To do so, the investigators will administer the adrenergic antagonist Carvedilol, which can cross the blood-brain barrier. The drug will be perorally administered before a nap in the MRI, in a double blind, placebo controlled manner. To assess sleep quality and function, cognitive testing will be performed before and after the nap in the MRI scanner. Moreover, to distinguish sleep and wakefulness, electroencephalographic (EEG) recordings will be performed during magnetic resonance (MR)-imaging. Because sleep is a strong homeostatic regulated process, sleep quality, duration and timing will be controlled by EEG monitoring, immediately prior to and during the study to ensure that data is intra- and inter-individually comparable.

Hypotheses:

Investigators hypothesis that the fMRI data collected awake and during a nap will be altered by the adrenergic treatment. Specifically, investigator propose the following hypotheses: 1. Sleep promotes cerebrospinal fluid pulsations (glymphatic flow) in the human brain, as measured with fMRI. 2. Challenging the sleep-homeostat by sleep deprivation promotes the fMRI glymphatic flow signal further. 3. The rate of glymphatic flow is expected to be proportional to simultaneously measured non-rapid eye movement EEG slow wave activity. 4: The adrenergic antagonist carvedilol will enhance glymphatic clearance and sleep intensity. 5. The fMRI determined glymphatic flow is associated with improved cognitive performance following sleep.

6. Enhanced glymphatic flow is correlated with enhanced cognitive performance, including:

assessments of visual attention, reaction time, paired-associative memory, working memory, emotional recognition and subjective ratings of sleepiness and mood.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: October 1, 2019
• Est. primary completion date: September 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Healthy volunteer (male or female) between 18 and 35 years.

• Good sleeper with sleep efficiency above 80%.

Exclusion Criteria:

• Current or former primary psychiatric disorder in volunteer of first degree relatives (DSM IV Axis I or WHO ICD-10 diagnostic classification).

• Current or previous neurological disease, severe somatic disease, or the consumption of drugs likely to influence the test results.

• Claustrophobia or fear of being in an MR-scanner.

• Alcohol or drug abuse.

• Regular smoking or nicotine addiction

• Extreme morning or evening type, or extreme short or long sleeper.

• Disordered sleep, regular shift-work or extreme tiredness (e.g. Epworth Sleepiness Scale (ESS) > 10).

• Crossing of multiple time zones within the last 6 months.

• Extreme use of stimulants such as caffeine.

• Not adhering to the prescribed sleep-wake schedule before study initiation.

• Left handedness.

• Obesity (BMI > 27.5).

• Non-fluent in Danish or pronounced visual or auditory impairments.

• Current or past learning disability.

• Large head size (>59 cm in circumference).

• Pregnancy

• Contraindications for MRI (pacemaker, metal implants, etc.).

• Allergy to the ingredients in the administered drug.

• Abnormal ECG (e.g. prolonged QT syndrome, etc.)

• Dizzy when changing from supine to upright position (e.g. postural orthostatic tachycardia syndrome).

• Mild hypotension (blood pressure below 100/70 mmHg)

• Hypertension (blood pressure above 140/90 mmHg).

Related Conditions & MeSH terms

• Sleep
• Sleep Deprivation
• Sleep Wake Disorders

Intervention

Drug:
• Carvedilol 25mg
Cross-over, randomized, placebo-controlled study.
• Placebo oral capsule
Cross-over, randomized, placebo-controlled study.

Locations

Country	Name	City	State
Denmark	Neurobiology Research Unit, Rigshospitalet	Copenhagen

Sponsors (3)

Lead Sponsor	Collaborator
Gitte Moos Knudsen	Center for translational Neuromedicine, University of Copenhagen, Denmark, Danish Center for Sleep Medicine

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure the change in functional Magnetic Resonance Imaging (fMRI)-detected glymphatic flow in wakefulness and sleep at baseline		Baseline compared to baseline - within same 1 day
Primary	Measure and compare functional Magnetic Resonance Imaging (fMRI)-detected glymphatic flow in baseline sleep and in sleep-deprived sleep		Baseline to follow-up 5±3 days
Primary	Measure and compare fMRI-detected glymphatic flow in placebo and carvedilol condition		Placebo compared to treatment 5±3 days apart.
Primary	Correlate fMRI-detected glymphatic flow with simultaneous detected EEG sleep slow wave activity		Nocturnal sleep compared to sleep during Magnetic Resonance scans within same 1 day.
Primary	Measure EEG slow wave activity during Magnetic Resonance imaging and compare Carvedilol with placebo to see how sleep is affected by the treatment		Placebo compared to treatment 5±3 days apart.
Primary	Measure if fMRI-detected glymphatic flow correlates with subjective sleepiness ratings		Measurements collected within the same 1 day
Primary	Measure fMRI-detected glymphatic flow and whether it correlates with cognitive performance before and after MR imaging		Measurements collected within the same 1 day
Primary	Measure fMRI-detected glymphatic flow and whether correlates with changes in cognitive performance from before to after MR imaging		Measurements collected within the same 1 day
Primary	Measure whether Carvedilol improves sleepiness after the MR scan compared to placebo		Measurements collected within the same 1 day
Primary	Measure whether Carvedilol improves cognitive performance (measurement: psychomotor vigilance test) after the MR scan compared to placebo		Measurements collected within the same 1 day
Secondary	Measure whether fMRI-detected glymphatic flow is spatially correlated with simultaneous EEG NREM slow wave activity		Measurements collected within the same 1 day
Secondary	Measure whether fMRI-detected glymphatic flow correlates with simultaneous NREM EEG activity		Measurements collected within the same 1 day
Secondary	Measure whether fMRI-detected glymphatic flow is positively correlated with sleep driven structural changes in T2 and diffusion weighted (DWI) images		Measurements collected within the same 1 day
Secondary	Measure whether Carvedilol modulates nocturnal recovery sleep (measurement: EEG slow wave activity) after sleep deprivation		Baseline to follow-up 5±3 days
Secondary	Measure whether the psychomotor vigilance test is modulated by carvedilol		Placebo compared to treatment 5±3 days apart.
Secondary	Measure whether the visual attention (measurement: Theory of Visual Attention task) is modulated by carvedilol		Placebo compared to treatment 5±3 days apart.
Secondary	Measure whether the visual attention (measurement: Theory of Visual Attention task) is modulated by sleep-deprivation		Baseline to follow-up 5±3 days
Secondary	Measure whether emotional memory performance (measurement: emotional word pair task) is modulated by carvedilol		Placebo compared to treatment 5±3 days apart.
Secondary	Measure whether emotional memory performance (measurement: emotional word pair task) is modulated by sleep-deprivation		Baseline to follow-up 5±3 days